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Strain dependent differences in 
glucocorticoid-induced bone loss 
between C57BL/6J and CD-1 mice
Adel Ersek1, Ana I. Espirito Santo1, Youridies Vattakuzhi1, Saumya George1, Andrew R. Clark2 
& Nicole J. Horwood1
We have investigated the effect of long-term glucocorticoid (GC) administration on bone turnover in 
two frequently used mouse strains; C57BL/6J and CD1, in order to assess the influence of their genetic 
background on GC-induced osteoporosis (GIO). GIO was induced in 12 weeks old female C57BL/6J 
and CD1 mice by subcutaneous insertion of long-term release prednisolone or placebo pellets. 
Biomechanical properties as assessed by three point bent testing revealed that femoral elasticity 
and strength significantly decreased in CD1 mice receiving GC, whereas C57BL/6J mice showed no 
differences between placebo and prednisolone treatment. Bone turnover assessed by microcomputer 
tomography revealed that contrary to C57BL/6J mice, prednisolone treated CD1 mice developed 
osteoporosis. In vitro experiments have underlined that, at a cellular level, C57BL/6J mice osteoclasts 
and osteoblasts were less responsive to GC treatment and tolerated higher doses than CD1 cells. Whilst 
administration of long-term release prednisolone pellets provided a robust GIO animal model in 12 
weeks old CD1 mice, age matched C57BL/6J mice were not susceptible to the bone changes associated 
with GIO. This study indicates that for the induction of experimental GIO, the mouse strain choice 
together with other factors such as age should be carefully evaluated.
Glucocorticoids (GC) are steroid hormones secreted by the adrenal cortex that are involved in metabolic, devel-
opmental and immunological regulation. In the past years synthetic GC were often used as anti-inflammatory 
agents in the treatment of rheumatoid arthritis (RA)1.
To research the onset and treatment options of different chronic inflammatory diseases several mouse mod-
els that carry different mutations or lack the activity of certain genes have been established2–4. These animal 
models were and are very useful in revealing the involvement of different pathways in specific inflammatory 
diseases. Nonetheless, in humans different treatment regimens involving long-term GC administration usually 
leads to osteopenia, a side effect that was also observed in Swiss mice and related strains such as the CD1 mice5–8. 
However, other relevant mouse strains used for chronic inflammatory diseases that are regularly subjected to GC 
treatment in their research regimen have been established on the C57BL/6J background2,9. Recently Thiele and 
et al., have shown that long-term GC treatment in C57BL/6 animal model does not result in significant bone loss 
as opposed to its effects in humans or in other glucocorticoid-induced osteoporosis (GIO) susceptible mouse 
strains. Thus, in an effort to obtain some subtle osteopenia they have recommended to substantially increase the 
GC dose in the C57BL/6 mice in comparison to other mouse strains10.
To date, the C57BL/6 strain is frequently used to generate transgenic and knockout mice used in RA and other 
inflammatory research, but the data on the GC treatment side effects especially GIO in these mice remains very 
poor with only a few studies and all of them using older mice7,11. Therefore, in an effort to determine the effects 
of long term GC treatment in vivo and in vitro we have compared 12 weeks old (skeletally mature) non-GIO 
susceptible C57BL/6J strain with 12 weeks old CD1 mouse (Swiss-Webster type mouse) commonly used for GC 
induced osteopenia studies. Further, we have evaluated the strain specific responses to experimentally induced 
osteoporosis in the two main bone cell populations that are actively involved in bone remodelling.
Overall, our results have shown that the two strains exibit different profiles of bone turnover markers and 
biomechanical properties when subjected to long term GC administration and different sensitivity to GCs at 
a cellular level. Whilst 12 weeks old CD1 mice proved to be a robust GIO animal model with bone cells highly 
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sensitive to low doses of GC, C57BL/6J mice were much less susceptible to GIO and bone cells from this strain 
were far less sensitive to GC exposure.
Materials and Methods
Animals and experimental procedures. 12 weeks old female C57BL/6J and CD1 mice (Charles River 
UK Ltd. Margate, UK) were maintained in Biological Services Unit, The Kennedy Institute of Rheumatology, 
University of Oxford (Oxford, UK). Animal care and experimental procedures were approved by the University 
of Oxford Local Ethical Review Committee under PPL 70-7335 and were conducted in accordance with the UK 
Home Office Animals Act of 1986. GIO was induced in C57BL/6J and CD1 mice by subcutaneously implanted 
slow release prednisolone (2.5 mg/60 days) or placebo pellets (Innovative Research of America, USA). Mice were 
sacrificed 56 days after pellet insertion.
In vitro osteoclast (OC) formation and tartrate resistant acid phosphatase (TRAP) assay. Bone 
marrow (BM) cells isolated from 12 weeks old C57BL/6J and CD1 mice were density separated with 
Lympholyte-M (Cedarlane, Burlington, USA) and the purified lymphocytes were cultured overnight at 37 °C in 
5% CO2 in complete medium: α -MEM with 10% foetal bovine serum (FBS), supplemented with 50 ng/ml murine 
macrophage colony stimulating factor (M-CSF) (Miltenyi, Abingdon, UK) and next day were plated at a density 
of 1 × 10^5 cells/well in 96-well plates where OC precursors were induced to proliferate and differentiate with 
(150 ng/ml) M-CSF and (10–100 ng/ml) receptor activator of NF-kB ligand (RANKL) (Miltenyi, Abingdon, UK) 
supplemented with 0–10^4 nM Dexamethasone (Dex) (Sigma-Aldrich, Gillingham, UK) as indicated. On day 6 
cells were washed with PBS and fixed with 4% paraformaldehyde (PFA), then permeabilized with acetone/ethanol 
1:1 solution and stained for TRAP activity for 15 mins at 37 °C (0.1 mg/ml Napthol AS-MX phosphate, 0.4 mg/ml 
Fast Red Violet LB Salt, 0.5 ml Dimethylformamide in 50 ml TRAP buffer; all from Sigma-Aldrich, Haverhill 
Suffolk, UK). Multinucleated (no. of nuclei ≥ 3) TRAP-positive cells that stained red were considered to be OCs. 
In all the experiments BM cells were also cultured in complete medium with M-CSF only served as negative 
control for OC formation.
In vitro osteogenensis assay. Murine calvarial osteoblasts (OBL) isolated as described previously12 at day 
1 of life by sequential enzymatic digestion with 1 mg/ml Collagenase II (Worthington, Lakewood, USA) and 
2 mg/ml Dispase (Invitrogen, Paisley, UK) in PBS12 were plated directly in 96 well plates at 5 × 10^4 cells/well 
in control medium (DMEM and 10% FBS) or osteogenic medium (DMEM supplemented with 10% FBS, 1 M 
β -glycerolphosphate, 50 mg/ml phosphoascorbic acid and 0–10^4 nM Dex). For evaluating mineralized calvarial 
bone nodules on day 6 of culture, cells were stained with 1% alizarin red-S (Sigma-Aldrich, Gillingham, UK). The 
alizarin red-positive area was analysed using NIH image software Image-J, version 1.45d (imagej.nih.gov/ij/) and 
expressed as a percentage of alizarin red-positive area over total area of the well13,14. In all the experiments OBL 
were also cultured in control medium as negative control for mineralization.
Microcomputer tomography (Micro-CT) analysis. Mouse lumbar vertebrae and tibia were harvested 
56 days after pellet insertion were fixed in 4% PFA and scanned with Skyscan 1174 scanner (SkyScan, Belgium), 
50 kV, 800 μ A, 8.3 μ m isometric voxel resolution, 0.7 degree rotation step with 0.5 mm Al filter and exposure set 
to 7008 ms and at 12.57 μ m image pixel size. Images were analysed using Skyscan CT Analyzer software version 
1.13.2.1.
Decalcified bone histology and histomorphometric analysis. Mouse vertebrae were fixed in 4% 
PFA at 4 °C. After 24 h of fixation, vertebrae were transferred into 10% EDTA for 21 days while changing the 
EDTA solution every 3–4 days. After paraffin embedding following the regular techniques, the bones were 
sectioned with Sakura Accu-Cut SRM 200 microtome (Japan). Sections (4 μ m) were stained for Masson’s tri-
chrome or TRAP activity and counterstained with 0.25% methyl green following the standard procedures. 
Immunohistochemistry for osteocalcin was performed following trypsin antigen retrieval then primary anti-
body overnight at 4 °C (Osteocalcin mouse polyclonal antibody produced in rabbit, ALX-210-333-C100, Enzo, 
used at final conc. 1 mg/ml). For non-specific control staining treat sections with isotype control antibody at a 
matched concentration (Rabbit IgG, polyclonal-Isotype Control, ab27478). A biotinylated secondary antibody 
(Biotinylated Goat anti-rabbit, ab64256, Abcam) was used for antibody detection before counterstaining with 
Mayers hematoxylin. Slides were viewed using Olympus Bx51 microscope (Japan) and pictures were taken with 
Olympus DP71 camera (Japan).
Histomorphometric analysis of bone volume, bone surface and determination of OC numbers and OC surface 
were carried out using the OsteoMeasure histomorphometry system (OsteoMetrics Inc. Atlanta, GA, USA) in 
accordance with ASBMR standard nomenclature on TRAP stained and methyl green counterstained histological 
sections as described15,16.
Three-point bend testing. Three-point bend testing was performed using an Instron 5942 materials-testing 
load frame and custom-built mounts that incorporated rounded supports to minimise cutting and shear loads 
(Instron® Limited, USA). The right femur of mice treated with placebo or prednisolone were cleaned of soft 
tissues and fixed in 70% ethanol at 4 °C. Prior to bend testing bones were rehydrated in PBS for two hours. 
Femurs were placed horizontally and centred on two support points and positioned with the anterior surface 
upward. Load was applied vertically downwards to the midshaft with a constant rate of displacement of 2 mm/sec 
until failure. Based on the load-deformation curve, the maximum load and elastic modulus was determined. The 
load-deformation curves were plotted using Bluehill 3 software (Instron® Limited, USA).
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Enzyme linked immunosorbent assay (ELISA). RatLaps EIA kit for determining serum 
carboxy-terminal telopeptide of type I collagen (CTX) was obtained from IDS (Immunodiagnostics Systems 
Ltd., Boldon, UK). ELISA Kit for murine Procollagen I N-terminal Propeptide (PINP) was obtained from Caltag 
Medsystems (UK). ELISA assays were performed according to the manufacturer’s instructions.
Statistical analysis. Statistical interpretation of the data was done using one-way analysis of variance 
(ANOVA) with a subsequent Tukey post-test determining the differences between the specific experimental 
groups. Data is represented as mean ± standard deviation (SD) or standard error of mean (SEM), as specified in 
figure legends. Statistical significance was set for a p value less than 0.05. All calculations were performed using 
GraphPad Prism version 5 software (GraphPad Prism, San Diego, USA).
Results
Experimental GIO models are well established in outbred Swiss Webster mice or other strains such as CD1 devel-
oped on Swiss Webster background, in which a loss of bone volume and trabecular connectivity is observed7,8,17. 
However, most genetically modified mice are established on the C57BL/6 background. To investigate whether 
C57BL/6 mice are less responsive to GIO, slow release pellets containing prednisolone (3.2 mg/kg/day) were 
implanted in 12 weeks old female C57BL/6J and CD1 mice for 56 days.
Biomechanical properties and microstructural characteristics in GC treated CD1 and C57BL/6 
mice bones. Bone strength and elasticity were evaluated by three-point bend testing of long bones. Femurs 
obtained from prednisolone treated CD1 mice had significantly lower elasticity and were able to withstand 
a significantly lesser load compared to the placebo treated mice, while C57BL/6 mice femurs biomechanical 
properties were not affected by GC treatment (Fig. 1a,b). Vertebral bone architectural parameters evaluated by 
micro-CT revealed that the prednisolone treatment in CD1 mice significantly decreased trabecular bone volume 
(BV/TV) and trabecular number (Tb.N), while the trabecular pattern factor (Tb.Pf) and structure model index 
(SMI) increased significantly. Nonetheless, prednisolone treatment in C57BL/6 mice had no significant effect on 
Figure 1. Bone biomechanical properties and structure analysis in C57BL/6J and CD1 mice treated with 
prednisolone or placebo. Femurs of female mice treated with placebo or 3.2 mg/kg/day prednisolone (GC) 
were harvested after 56 days and three-point bend testing was performed to test (a) elastic modulus and  
(b) maximum load. Lumbar vertebrae were analysed by microCT and (c) trabecular bone volume (BV/TV), 
(d) trabecular number, (e) trabecular pattern factor and (f) structure model index (SMI) were evaluated (n = 5 
mice/group) in case of C57BL/6J (BL6) and CD1 mice. Error bars correspond to SD. Statistical analysis was 
performed using one-way ANOVA and Tukey’s multiple comparison test evaluated differences between groups 
(*p < 0.05, **p < 0.001).
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vertebral trabecular parameters (Fig. 1c–f). This can be clearly visualised by 2D and 3D images of the tibia from 
these mice where the decrease in trabecular structure is seen in the CD1 mice yet the C57BL/6 mice have pre-
served trabecular parameters following GC treatment (Fig. 2a,c).
Figure 2. (a) Original unsegmented image of mouse proximal tibia cross-section placebo and prednisolone 
treated C57Bl/6J and CD1 mice. (b) 2D measurement of cortical thickness of placebo and prednisolone treated 
C57Bl/6J and CD1 mice. Error bars correspond to SEM. Statistical analysis was performed using unpaired t-test 
(*p < 0.05). (c) 3D micro-CT reconstruction of mouse proximal tibia cross-section placebo and prednisolone 
treated C57Bl/6J and CD1 mice. (d) PINP levels in serum samples of C57BL/6J and CD1 mice treated with 
either prednisolone or placebo. Error bars correspond to SEM. (e) Representative histological sections of mouse 
lumbar vertebrae stained for Masson Trichrome (magnification 4x). (f) Representative histological sections of 
mouse lumbar vertebrae stained for osteocalcin (magnification 4x).
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Examination of the cortical bone thickness likewise showed that there was a significant loss of bone in the 
CD1 mice following prednisolone treatment whereas the C57BL/6 mice did not lose cortical bone in response to 
treatment with GC (Fig. 2a,b). The loss in both cortical and trabecular thickness in the CD1 mice would account 
for the reduction in bend strength seen in Fig. 1a,b.
In vivo osteoblast parameters were unchanged between CD1 and C57BL/6 mice. To assess the 
effects of prednisolone treatment on osteoblast parameters in vivo we collected serum from the mice at sacrifice 
and assessed the levels of murine procollagen I N-terminal propeptide (PINP) as a measure of osteoblast activity. 
There was no significant difference between the CD1 mice and C57BL/6 mice either with or without GC treat-
ment (Fig. 2d). The bone architecture of the vertebrae was investigated by Masson’s trichrome staining and the 
distribution of osteoblasts was visualized by immunohistochemistry for osteocalcin, a mature osteoblast protein 
(Fig. 2e,f). There were no observable differences between the two different mouse strains therefore the effects of 
osteoclasts (OC) were next investigated.
Osteoclastogenesis and OC activity in Prednisolone treated CD1 and C57BL/6 mice in vivo. 
Histological analysis of the vertebrae performed after TRAP staining that identified OCs by red staining showed 
significantly increased OC numbers and surface area in the prednisolone treated CD1 mice compared to the pla-
cebo group, but no significant differences were observed in the case of C57BL/6 mice (Fig. 3a–c). To determine 
OC resorptive activity and bone turnover in vivo, serum was taken by cardiac puncture from prednisolone or 
placebo treated mice at the end of experiment and analysed for C-terminal telopeptides of collagen type I (CTX) 
Figure 3. Bone histology and histomorphometry in placebo or prednisolone treated C57BL/6J and 
CD1 mice. Representative histological sections of mouse lumbar vertebrae (a) stained for OC TRAP activity 
and counterstained with 0.25% methyl green solution (magnification 20x). (b,c) Bone histomorphometry 
parameters obtained by analysing the histological sections of lumbar vertebrae from mice (n = 5 mice/group) 
from C57BL/6J (BL6) and CD1 mice treated with placebo or prednisolone (GC); Number of osteoclasts/total 
bone area (N.Oc/T.Ar); OC surface is expressed as percent of total bone surface (Oc.S/BS). (c) Serum values 
of CTX (ng/ml). Error bars correspond to SD. Statistical analysis was performed using one-way ANOVA and 
Tukey’s multiple comparison test evaluated differences between groups (*p < 0.05, **p < 0.01).
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by ELISA. CTX levels showed a significant increase in response to long-term prednisolone administration in CD1 
mice, but no effect was observed in the case of C57BL/6 mice (Fig. 3d).
Effect of Dexamethasone on in vitro osteoclastogenesis in CD1 and C57BL/6 mice cells. In 
order to analyse the effect of GC on the main cellular components of the bone we induced BM cells from CD1 
and C57BL/6 mice to form OCs in vitro by using M-CSF and different doses of RANKL (10, 50, 100 ng/ml) in the 
presence or absence of 100 nM Dex. In the absence of RANKL no OC were formed from either mouse strain BM 
(data not shown) and RANKL stimulated osteoclastogenesis dose dependently in both mouse strains (Fig. 4a,b). 
In the presence of RANKL, the addition of 100 nM Dex significantly increased OC numbers in the CD1 cultures, 
but not in the C57BL/6 BM cultures (Fig. 4a,b). To assess how different doses of Dex might influence osteoclas-
togenesis in CD1 and C57BL6 cells, overnight cultured murine BM cells (with 50 ng/ml M-CSF) were induced to 
form OCs with 150 ng/ml M-CSF and 100 ng/ml RANKL (the doses with the highest osteogenic potential) and 
with increasing concentrations of Dex (0, 10^1, 10^2, 10^3 and 10^4 nM). In CD1 mice the addition of Dex at 
low and medium doses (10^1 and 10^2 nM) significantly stimulated osteoclastogenesis while high doses of Dex 
(10^3, 10^4 nM) inhibited OC formation compared to the 10^2 nM dose (Fig. 4c,d). In case of C57BL/6 mice 
OC numbers and OC size were increased significantly only at higher doses (10^3, 10^4 nM) of Dex (Fig. 4c,d).
Effect of Dexamethasone on in vitro bone nodule formation in CD1 and C57BL/6 mice cells. 
Another major bone cell type affected by GC excess is the osteoblast (OBL). We did not observe any in vivo effects 
on PINP serum levels and osteocalcin staining by histology (Fig. 2d–f) however assessing the direct effects on 
osteoblasts in isolation was investigated to determine whether these cells on their own are similarly less sensitive 
to GC like the OC (Fig. 4). In order to assess the GC osteogenic induction potential on C57BL/6 and CD1 OBLs, 
calvarial OBLs were isolated from 1 day old pups and cultured in control or osteogenic medium followed by 
identifying the mineralized calvarial bone nodules by alizarin red-S staining on day 6 of culture. Alizarin red-S 
staining revealed that the addition of phosphoascorbic acid and β -glycerolphosphate induced mineralization of 
calvarial OBLs in both mouse strains (Fig. 5a); however culturing OBLs only in control media did not result in 
mineralization (results not shown). The addition of Dex in different concentrations (0, 10^1, 10^2, 10^3 nM) to 
C57BL/6 mice OBLs did not significantly influence the bone nodule forming capacity of these cells, however a 
slight trend of dose response could be observed (higher doses of Dex seemed to induce more calcium deposition) 
(Fig. 5a,b). Bone nodule formation and mineralization in the case of CD1 OBLs was increased significantly by 
10^2 nM Dex, while the high concentration of 10^3 nM inhibited OBL mineralization and bone nodule forma-
tion (Fig. 5a,b).
Discussion
To date, corticosteroids are frequently used in the treatment of various chronic inflammatory diseases due to their 
potent anti-inflammatory immunosuppressive actions. However, corticosteroids are well known to cause osteo-
penia after long-term use and this side effect can cause major problems in clinical practice1,18. Several factors that 
facilitate GIO development have already been decoded19,20 but identification of still unknown regulators/inducers 
is presently on going with different transgenic and/or knockout mice.
As most genetically modified mice have been developed on C57BL/6 background we sought to compare the 
C57BL/6 strain propensity to develop GIO with CD1 mice that are regularly used as a well-established GIO 
experimental animal model. It is important to note that at baseline there is a significant difference in bone param-
eters, including maximum load, BV/TV, and cortical and trabecular thickness, between the CD1 and C57BL/6 
mice. This has previously been reported and the C57BL/6 mice are known to have low skeletal mass compared to 
other mouse strains21. The CD1 mice are an outbred strain derived from the Swiss Webster mice and are known 
to have a significantly higher skeletal bone mass. As such it could be proposed that the C57BL/6 mice simply 
have less bone to lose and hence why GC treatment fails to obtain significant effect, however, this is an unlikely 
explanation as C57BL/6 mice are frequently used for ovariectomy-induced bone loss studies where a significant 
reduction in bone parameters is observed following estrogen withdrawl22.
The mechanical properties of bone are dependent on its composition (i.e. porosity and mineralization) and 
organisation (i.e. trabecular and cortical bone architecture, collagen fibre orientation); a decrease in bone mineral 
mass and density leads to a loss of bone stiffness and an increased fracture risk. As the first sign of osteoporosis is 
loss of bone strength and elasticity that often precede osteopenia we have evaluated these indices in the femur by 
using three-point bend testing. The three-point bend testing revealed that prednisolone treated CD1 femurs had 
reduced elasticity and tolerated less load compared to placebo treated mice whereas the biomechanical properties 
of C57BL/6 mice femurs were not affected by GC treatment.
Vertebral bone architectural parameters in prednisolone treated CD1 mice were characteristic of an osteo-
porotic trabecular structure with significantly reduced trabecular bone volume11 and trabecular number and 
increased trabecular pattern factor indicating lower trabecular bone connectivity. The structural model index 
was also increased in the GC treated CD1 mice indicating a transition of trabecular bone from plate-dominated 
to rod-dominated structures, a phenomenon often associated with bone fragility23. However, vertebral trabecular 
parameters in C57BL/6 mice in our experiments were not influenced by long term GC administration.
Histological analysis of the lumbar vertebrae after TRAP staining revealed that long term GC administra-
tion increased the number of OCL on the trabecular bone surface in case of the CD1 mice but did not affect 
significantly the C57BL/6 mice. As serum CTX levels act as marker of increased bone resorption due to OCL 
over activation in osteoporosis24, serum CTX was tested in prednisolone and placebo treated mice. Only CD1 
mice presented increased serum CTX levels in response to long term CG treatment indicating accentuated bone 
resorption whilst C57BL/6 mice CTX levels were not affected.
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Figure 4. In vitro OC differentiation of C57BL/6J and CD1 cells in the presence of Dex. Overnight cultured 
(with 50 ng/ml M-CSF) C57BL/6J and CD-1 mice BM cells were plated in 96-well plates and treated with 
150 ng/ml M-CSF and increasing doses of RANKL (10, 50, 100 ng/ml) in the presence or absence of 100 nM 
Dex. (Pictures in upper row were obtained from CD1 mice and pictures in lower row were obtained from 
C57BL/6 mice) (a) and TRAP positive multinucleated cells per 10X field were enumerated (b). Overnight 
cultured murine cells were induced to form OC with 150 ng/ml M-CSF and 100 ng/ml RANKL and with 
increasing concentrations of Dex (0, 10^1, 10^2, 10^3 and 10^4). (Pictures in upper row were obtained from 
CD1 mice and pictures in lower row were obtained from C57BL/6 mice) (d) and TRAP positive multinucleated 
cells per 10X field were counted (c). All pictures were taken with 20X magnification. A representative 
experiment of 3 (n = 3), each performed in triplicate assays is shown (a, b, c and d). Error bars correspond to 
SD. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparison test 
(*p < 0.05, **p < 0.005, ****p < 0.0001).
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In contrast to our in vivo findings, several studies do report successful induction of osteopenia in C57BL/6 
mice after long term GC administration, but it is notable that in each case the mice were over 5 months of age at 
the start of the experiment and the GC induced bone loss was subtle10,25. We can just speculate that the mecha-
nisms that prevent GIO induction in younger C57BL/6 mice may become apparent with advancement in age i.e. 
the increase in bone marrow fat at the expense of osteoblast formation that occurs with age. Furthermore, our 
result is partially in accordance with a study conducted by Weinstein, who found that in 6 month old C57BL/6 
mice Cathepsin-K and Calcitonin receptor mRNA expression was not altered by prednisolone administration 
and in situ OC numbers were not affected either, but they observed a moderately reduced bone mineral density 
in the GC treated mice26.
As our in vivo data and several other studies suggest that OC development and activity is altered during long 
term GC exposure27–31 and knowing that OCs have an important role in the onset of the GIO32,33, we induced CD1 
and C57BL/6 BM cells to from OCs in vitro. These studies revealed that OCs from CD1 mice displayed increased 
responsiveness to low doses of Dex and increased sensitivity to high doses of Dex. In the C57BL/6 mice low doses 
of Dex did not affect ostoclastogenic potential however the addition of high doses of Dex stimulated osteoclas-
togenesis and possibly also OC fusion or spreading as the OC size was increased as observed by visual inspection. 
Thus, our data obtained with C57BL/6 mice cells contradicts the literature where Dex was shown to have inhib-
itory effect, however the inhibitory effect of Dex on CD1 OCs is in agreement with previously published data29. 
It is worth mentioning that the study conducted by Kim et al., assessed only the C57BL/6 and not the CD1 BM 
cells response to different doses of Dex, and significant differences between the experimental conditions (e.g. OC 
purification) may have produced this inconsistency29. Nevertheless, in our hands CD1 mice OCs proved to be 
Figure 5. In vitro osteogenesis of C57BL/6J and CD1 mouse calvarial cells in the presence of Dex. Calvarial 
OBL were isolated from 1 day old pups by collagenase II + Dispase enzymatic digestion and were plated in 96 
well plates in osteogenic induction media with different Dex concentrations (0, 10^1, 10^2 and 10^3 nM). OBL 
mineralization was evaluated on day 6 by 1% alizarin red-S staining (Original magnification, x4, Pictures in 
upper row were obtained from CD1 mice and pictures in lower row were obtained from C57BL/6 mice) (a). The 
percentage of Alizarin red-positive bone nodules area reported to the total well area was quantified with Image-J 
software. Results are represented as mean of 4 (n = 4) independent experiments, each performed in triplicates 
(b). Error bars correspond to SEM. Statistical analysis was performed using one-way ANOVA followed by 
Tukey’s multiple comparison test (*p < 0.05, **p < 0.005).
www.nature.com/scientificreports/
9Scientific RepoRts | 6:36513 | DOI: 10.1038/srep36513
far more sensitive to the in vitro culture conditions regarding the Dex dose than the C57BL/6 cells. Furthermore, 
our data explains at least partially why the CD1 mice in vivo had increased OC numbers after GC treatment and 
showed increased propensity to develop GIO, but not the C57BL/6 mice.
Decreased OBL activity leading to reduced new bone formation due to long term GC administration is now 
considered to be one of the main causes of GIO32,34. Changes in OBL activity in vivo were not detected, most 
likely as these measurements were taken at the end stage of the disease. As previously reported, in our study phos-
phoascorbic acid and β -glycerolphosphate was sufficient in vitro to provide an inductive effect for OBL mineral-
ization in both mouse strains35,36. Moreover, the ability of Dex at 10^2 nM dose to stimulate OBL mineralization 
is also in accordance with previous studies showing that GCs at physiological levels and GC signalling stimulate 
bone mineralization and bone development37,38. It is of importance to mention that the dose of 10^2 nM Dex 
represents the regular dose used for OBL induction media in most of the published recipes38,39. However, when 
the Dex dose was increased its detrimental effect became recognizable in the CD1 mice calvarial OBL cultures 
but not in the C57 BL/6 cell cultures.
Overall, CD1 mice responded as expected to long term GC treatment and it appears that prednisolone stim-
ulated OCL maturation, activity and possibly life span26,28,29 leading to sustained bone loss40. As to why 12 weeks 
old C57BL/6 mice were not responsive to long term GC administration and eluded experimental GIO induction 
was revealed by in vitro studies. Both major bone cell types: OC and OBL from CD1 and C57BL/6 mice displayed 
different sensitivity levels towards different doses of Dex in vitro; CD1 cells were much more sensitive to reduced 
doses of GC as opposed to C57BL/6J bone cells that tolerated higher doses and seemed to be resistant to the del-
eterious effects of Dex administration. It is this inequality of OC and OBL sensitivity to different doses of GC in 
CD1 and C57BL/6J mice that we propose leads to the strain dependent differences in GIO susceptibility.
To our knowledge this is the first study that compares the CD1 and C57BL/6 strains susceptibility for the 
induction of experimental GIO in young animals (12 weeks) in depth and analyses the cellular components of 
bone that play critical role in GIO induction. Here we have demonstrated that GIO can be successfully established 
in the 12 weeks old CD1 mice but not in the C57BL/6 mice and infers that the genetic variability between these 
strains significantly contributes to the bone loss associated with long term GC administration. The differences 
reported here between the C57BL/6 and CD1 mice provide useful information that allows researchers to choose 
the appropriate genetic background for experimentally inducing GC related osteopenia and for the development 
of future transgenic and knockout mice involved in GIO research.
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